Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma

NCT06831175 is registered in ClinicalTrials.gov with West China Hospital as lead sponsor.

NCT NCT06831175
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06831175 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma
Lead sponsor
West China Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
March 15, 2025
Completion date
December 31, 2031
Enrollment
28 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adrenal cancer, adrenal cortical cancer, adrenal cortical carcinoma